For the quarter ended December 2024, Stryker (SYK) reported revenue of $6.44 billion, up 10.7% over the same period last year. EPS came in at $4.01, compared to $3.46 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $6.35 billion, representing a surprise of +1.34%. The company delivered an EPS surprise of +3.62%, with the consensus EPS estimate being $3.87.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Stryker performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales by Geography- International: $1.56 billion versus $1.63 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.1% change.
- Net Sales by Geography- United States: $4.87 billion versus $4.68 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +11.9% change.
- Net Sales by Business- Orthopaedics and Spine: $2.55 billion versus $2.59 billion estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +7% change.
- Net Sales by Business- MedSurg and Neurotechnology: $3.88 billion compared to the $3.76 billion average estimate based on nine analysts. The reported number represents a change of +13.3% year over year.
- Net Sales by Business- Orthopaedics and Spine- Knees: $687 million versus $673.11 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +9.1% change.
- Net Sales by Business- Orthopaedics and Spine- Spine: $186 million versus $337.22 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -41.5% change.
- Net Sales by Business- Orthopaedics and Spine- Hips: $463 million versus $457.61 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +11.8% change.
- Net Sales by Business- Orthopaedics and Spine- Other: $222 million compared to the $176.23 million average estimate based on seven analysts. The reported number represents a change of +33.7% year over year.
- Net Sales by Business- Orthopaedics and Spine- Trauma and Extremities: $996 million versus the seven-analyst average estimate of $935.04 million. The reported number represents a year-over-year change of +15.8%.
- Net Sales by Business- MedSurg and Neurotechnology- Instruments: $790 million compared to the $811.02 million average estimate based on seven analysts. The reported number represents a change of +7.3% year over year.
- Net Sales by Business- MedSurg and Neurotechnology- Endoscopy: $1.01 billion versus $971 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +12.8% change.
- Net Sales by Business- MedSurg and Neurotechnology- Medical: $1.14 billion versus the seven-analyst average estimate of $1.16 billion. The reported number represents a year-over-year change of +9.6%.
Shares of Stryker have returned +10.4% over the past month versus the Zacks S&P 500 composite's +0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>Stryker Corporation (SYK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
